Drug intelligence / Profile preview

OTV

Development stage: Preclinical
Lead developer: Denali Therapeutics
Administration: Intravenous, Subcutaneous

Overview

**OTV** is a non-specific Denali Therapeutics research designation rather than a single uniquely identifiable drug. In the provided context, OTV refers to preclinical neurodegeneration programs that include **OTV:MAPT**, described as a microtubule-associated protein tau inhibitor, and **OTV:SNCA**, described as an alpha-synuclein inhibitor. Publicly available information in the supplied context does not disclose the precise active ingredient, final molecular format, route, dosage form, or detailed construct-level modality for the umbrella term OTV itself.

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on OTV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OTV.

Explore the full profile